To date, the few medications with proven effectiveness in COVID-19 are appropriate primarily for the treatment of severely ill, hospitalized patients in well-resourced healthcare settings. WHO recommends the use of monoclonal antibody treatment for people with early-stage COVID-19, but these treatments too are expensive and complex to use in resource-constrained settings. No proven medications for uncomplicated COVID-19 are widely available in low- and middle-income countries.
So where are we today with new and emerging therapeutics that would be both effective and affordable in preventing the progression of mild or moderate COVID-19 and thereby prevent hospitalization? A couple of promising treatments have emerged recently, with early efforts underway to make these drugs more available than COVID-19 vaccines have been. What are the current research priorities, and do current efforts meet the needs?
The COVID-19 Clinical Research Coalition hosted a webinar that:
• Summarized the therapeutics development landscape for COVID-19
• Discussed the challenges in prioritizing drugs to be studied
• Assessed the treatment needs in low- and middle-income countries
• Discussed the challenges of ensuring affordable access to new therapeutics, and what can be done now to ensure equitable access globally to proven medicines.
Watch the recording
Slides presented during the webinar